塔达拉菲尔使用与患有良性前列腺增生症的男性的2型糖尿病发病率较低有关:基于人口的队列研究
Atsushi Takayama1, Satomi Yoshida2, Koji Kawakami1
1Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan.
Journal of internal medicine
|September 17, 2024
概括
在患有良性前列腺增生症 (BPH) 的男性中,塔达拉菲尔的使用与2型糖尿病 (T2DM) 的发病率较低有关. 这表明,tadalafil可能有助于预防T2DM在这个患者群体.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 塔达拉菲尔用于治疗良性前列腺激增症 (BPH).
- 建议在2型糖尿病 (T2DM) 中使用塔达拉菲尔对血糖控制的潜在益处.
- 长期使用塔达拉菲尔和T2DM发病率缺乏调查.
研究的目的:
- 调查塔达拉菲尔使用与发展T2DM的风险之间的关联.
- 为了比较用tadalafil治疗的BPH患者T2DM发病率与阿尔法抑制剂.
主要方法:
- 使用日本基于人口的索赔数据库模拟了一个目标试验.
- 包括BPH患者在没有先前糖尿病诊断或使用降血糖药物的情况下开始服用tadalafil或α-阻断剂.
- 主要结局:T2DM的发生率. 使用聚合后勤回归来分析风险比率 (RRs) 和累计发病率差异 (CIDs).
主要成果:
- 5180名参与者开始服用塔达拉菲尔,而20 049名参与者开始服用α阻断剂.
- 在tadalafil使用者中,T2DM的发病率为每1000人年5.4,在α-阻断剂使用者中为8.8.
- 塔达拉菲尔的开始与T2DM风险降低有关 (RR:0.47;95% CI:0.390.62).
结论:
- 与阿尔法阻断剂治疗的BPH男性相比,用达拉菲尔治疗的BPH男性的T2DM发病率较低.
- 塔达拉菲尔在BPH患者中显示出作为T2DM预防剂的潜力.
- 研究结果表明,在T2DM预防方面,塔达拉菲尔可能比α-阻断剂更有好处.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
134
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
134
Disorders of the Male Reproductive System
354
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
354
Oral Hypoglycemic Agents: Biguanides and Glitazones
182
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
182
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Antihypertensive Drugs: Thiazide-Class Diuretics
558
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
558
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146


